Literature DB >> 34661731

Temporal variation of optical coherence tomography biomarkers as predictors of anti-VEGF treatment outcomes in diabetic macular edema.

Emilia Maggio1, Maurizio Mete2, Mauro Sartore2, Francesco Bauci2, Massimo Guerriero2,3, Antonio Polito2, Grazia Pertile2.   

Abstract

PURPOSE: To report a longitudinal analysis of specific optical coherence tomography (OCT) features in eyes with diabetic macular edema (DME) treated with anti-VEGF.
METHODS: A total of 133 eyes of 103 consecutive patients with center-involving DME were included in the study. The eyes were treated between August 2008 and April 2019 with three monthly intravitreal anti-VEGF injections, either with or without prompt or deferred laser, followed by pro re nata (PRN) re-treatment. The following OCT biomarkers were evaluated: subfoveal neuroretinal detachment (SND) (defined as present (SND+) or absent (SND-)), hyperreflective retinal foci (HRF) number (defined as: absent/few(HRF-) or moderate/many (HRF+)), external limiting membrane (ELM) integrity, central macular thickness (CMT), and central retinal thickness (CRT). Changes in SND status and in the number of HRF were evaluated at each DME recurrence throughout the follow-up(FU) period. Mutual correlation among OCT biomarkers and their relationship with visual and anatomic outcomes were assessed both at baseline and over the FU period.
RESULTS: The mean FU was 71.2 months (SD 28.4; min. 12-max. 111). At baseline, the prevalence of SRD+ was 27.8% and a high number of HRF were detected in 41.4% of the eyes. A significant reduction in the number of HRF, CMT, CRT, and in the prevalence of SND was recorded in the post-loading phase (p-value <0.0001). In DME recurrences, the presence of SND+ and HRF+ was significantly more frequent in eyes with baseline SND+ and HRF+ compared to eyes presenting baseline SND- and HRF- (p-value <0.0001). No role of SND (p-value: 0.926) and HRF (p-value: 0.281) as baseline predictors of visual and anatomic outcomes was demonstrated, while a worse visual outcome was significantly correlated with a higher incidence of relapsing SND+ (p-value <0.0001) and HRF+ (p-value <0.0028) throughout the FU period.
CONCLUSION: In this study, SND and HRF were frequently present in DME recurrences with the same pattern exhibited at baseline, suggesting that these OCT biomarkers may characterize a specific pattern of DME that repeats over time. Moreover, the results suggested that the persistence and recurrence of SND and HRF may account for a decrease in visual function more than the baseline prevalence of these biomarkers. Further studies are required to confirm these findings.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Anti-VEGF treatment; Biomarkers; Diabetic macular edema; Optical coherence tomography; Outcome predictors; Temporal evolution

Mesh:

Substances:

Year:  2021        PMID: 34661731     DOI: 10.1007/s00417-021-05387-7

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  26 in total

1.  The correlation between fluorescein angiographic and optical coherence tomographic features in clinically significant diabetic macular edema.

Authors:  Se Woong Kang; Choul Yong Park; Don-Il Ham
Journal:  Am J Ophthalmol       Date:  2004-02       Impact factor: 5.258

2.  Optical coherence tomography features during the evolution of serous retinal detachment in patients with diabetic macular edema.

Authors:  David Gaucher; Clemence Sebah; Ali Erginay; Belkacem Haouchine; Ramin Tadayoni; Alain Gaudric; Pascale Massin
Journal:  Am J Ophthalmol       Date:  2007-12-11       Impact factor: 5.258

3.  Serous macular detachment in diabetic cystoid macular oedema.

Authors:  Hakan Ozdemir; Murat Karacorlu; Serra Karacorlu
Journal:  Acta Ophthalmol Scand       Date:  2005-02

4.  Functional and Anatomical Outcomes in Patients With Serous Retinal Detachment in Diabetic Macular Edema Treated With Ranibizumab.

Authors:  Audrey Giocanti-Aurégan; Linda Hrarat; Lise M Qu; Valérie Sarda; Marouane Boubaya; Vincent Levy; Gilles Chaine; Franck Fajnkuchen
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-02-01       Impact factor: 4.799

5.  Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema.

Authors:  Roxane J Hillier; Elvis Ojaimi; David T Wong; Michael Y K Mak; Alan R Berger; Radha P Kohly; Peter J Kertes; Farzin Forooghian; Shelley R Boyd; Kenneth Eng; Filiberto Altomare; Louis R Giavedoni; Rosane Nisenbaum; Rajeev H Muni
Journal:  JAMA Ophthalmol       Date:  2018-04-01       Impact factor: 7.389

6.  Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema.

Authors:  Stela Vujosevic; Tommaso Torresin; Silvia Bini; Enrica Convento; Elisabetta Pilotto; Raffaele Parrozzani; Edoardo Midena
Journal:  Acta Ophthalmol       Date:  2016-10-24       Impact factor: 3.761

7.  Diabetic Macular Edema With and Without Subfoveal Neuroretinal Detachment: Two Different Morphologic and Functional Entities.

Authors:  Stela Vujosevic; Tommaso Torresin; Marianna Berton; Silvia Bini; Enrica Convento; Edoardo Midena
Journal:  Am J Ophthalmol       Date:  2017-07-04       Impact factor: 5.258

Review 8.  Local and Systemic Inflammatory Biomarkers of Diabetic Retinopathy: An Integrative Approach.

Authors:  Stela Vujosevic; Rafael Simó
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-05-01       Impact factor: 4.799

9.  Peripheral blood metabolic and inflammatory factors as biomarkers to ocular findings in diabetic macular edema.

Authors:  Marc Figueras-Roca; Blanca Molins; Anna Sala-Puigdollers; Jessica Matas; Irene Vinagre; José Ríos; Alfredo Adán
Journal:  PLoS One       Date:  2017-03-22       Impact factor: 3.240

10.  Approach for a Clinically Useful Comprehensive Classification of Vascular and Neural Aspects of Diabetic Retinal Disease.

Authors:  Michael D Abramoff; Patrice E Fort; Ian C Han; K Thiran Jayasundera; Elliott H Sohn; Thomas W Gardner
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-01-01       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.